Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review

November 2021 | 47 pages | ID: P930BE630DAEN
GlobalData

Abstracts

Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Paratek Pharmaceuticals Inc (Paratek) develops and commercializes therapies based on tetracycline chemistry. Nuzyra (Omadacycline), the company’s lead product candidate is an USFDA approved broad spectrum antibiotic for the treatment of adults with community acquired bacterial pneumonia, acute bacterial skin and skin structure infections caused by susceptible bacteria. Its other product Seysara (sarecycline) is also an USFDA approved drug for the treatment of inflammatory acne vulgaris in patients with aged nine or older. Omadacycline is also being evaluated for the treatment of female patients with uncomplicated urinary tract infection and acute pyelonephritis. Paratek is headquartered in Boston, Massachusetts, the US.

Paratek Pharmaceuticals Inc Key Recent Developments

Nov 08,2021: Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
Nov 01,2021: Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021
Nov 01,2021: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 01,2021: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 09,2021: Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Paratek Pharmaceuticals Inc - Key Facts
Paratek Pharmaceuticals Inc - Key Employees
Paratek Pharmaceuticals Inc - Key Employee Biographies
Paratek Pharmaceuticals Inc - Major Products and Services
Paratek Pharmaceuticals Inc - History
Paratek Pharmaceuticals Inc - Company Statement
Paratek Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Paratek Pharmaceuticals Inc - Business Description
Paratek Pharmaceuticals Inc - Corporate Strategy
Paratek Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Paratek Pharmaceuticals Inc - Strengths
Paratek Pharmaceuticals Inc - Weaknesses
Paratek Pharmaceuticals Inc - Opportunities
Paratek Pharmaceuticals Inc - Threats
Paratek Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Paratek Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 08, 2021: Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
Nov 01, 2021: Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021
Aug 09, 2021: Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
Aug 03, 2021: Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021
Aug 02, 2021: Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021
Jun 14, 2021: Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors
May 17, 2021: Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement
May 17, 2021: Paratek Pharmaceuticals announces first Quarter 2021 Financial Results & Corporate Update
Feb 18, 2021: Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Feb 17, 2021: Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Paratek Pharmaceuticals Inc, Key Facts
Paratek Pharmaceuticals Inc, Key Employees
Paratek Pharmaceuticals Inc, Key Employee Biographies
Paratek Pharmaceuticals Inc, Major Products and Services
Paratek Pharmaceuticals Inc, History
Paratek Pharmaceuticals Inc, Other Locations
Paratek Pharmaceuticals Inc, Subsidiaries
Paratek Pharmaceuticals Inc, Key Competitors
Paratek Pharmaceuticals Inc, Ratios based on current share price
Paratek Pharmaceuticals Inc, Annual Ratios
Paratek Pharmaceuticals Inc, Annual Ratios (Cont...1)
Paratek Pharmaceuticals Inc, Interim Ratios
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Paratek Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Paratek Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Paratek Pharmaceuticals Inc, Ratio Charts
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021